Powdered Non Blood Derived Recombinant Human Fibronectin

Non - Blood Derived Recombinant Human Fibronectin for FN Detection in Type 2 Diabetes

Specification

Fibronectin (FN) is a particularly important and well-studied component of the extracellular matrix, and is known to play a key role in cell adhesion, spreading, migration, differentiation and proliferation via interactions with transmembrane integrin receptors. FN is a 220 kDa glycoprotein composed of 2 subunits bound via a disulfide bond, and exists as a soluble circulating protein in body fluids like plasma, but can be rearranged to a fibrillar insoluble component in the extracellular matrix of cells. FN possesses an acidic isoelectric point, and so is negatively charged at a physiological pH (7.4).

FN has a variety of biological activities. Modern medical research has shown that the change of fibronectin content is closely related to various clinical diseases, such as gastrointestinal tumors, and the detection of fibronectin content has very important clinical significance in the patient with gastrointestinal tumors.

Studies have shown that plasma fibronectin in patients with type 2 diabetes is significantly reduced. After treatment with hypoglycemic drugs, the fasting blood glucose decline is not obvious, but the plasma fibronectin rises significantly, and is negatively correlated with fasting blood glucose. Therefore, dynamic monitoring of pFN has certain clinical value for observing the condition of diabetic patients.

Nowadays, the commercial FN which are used to prepare FN polyclonal antibody are almost derived from the plasma, which is limited by the availability of blood supply and source. Secondly, blood-derived pFN sometimes affects the results due to high background values, leading to false positives. In addition, due to shortage of plasma and low expression levels of recombinant fibronectin in conventional gene expression systems, Healthgen Biotech is focusing on developing, manufacturing and marketing a series of environmental friendly and safe products by using the State-of-the-Art platform called Oryz^HiExp, having high capacity to express proteins or small peptides in the rice grain. The recombinant fibronectin (OsrhFN) was expressed in the rice endosperm platform using the world's top purification processing. The OsrhFN has been demonstrated that has the same physical and chemical with the plasma derived FN, and has more than 95% purity.

Detail

Other Names: OsrhFN, Recombinant FN, rhFN

Purity: Greater than 95% as determined by SDS-PAGE

Source: Rice Grain (Oryza Sativa)

Species: Human

Physical Appearance: Off-white lyophilized powder

Endotoxin: Less than 0.5EU/μg

Storage and Handling: Stored at temperatures -20℃ for 24 months

Amino Acid Sequence: Same as the Fibronectin from extracellular matrix

Supplemental Description

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding.